Patents by Inventor Catherine Leblanc

Catherine Leblanc has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
    Publication number: 20160304489
    Abstract: The present invention relates to particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, to a process of making said particles, to pharmaceutical compositions comprising said particles and to method of treating cancers using said pharmaceutical compositions.
    Type: Application
    Filed: March 18, 2016
    Publication date: October 20, 2016
    Applicant: NOVARTIS AG
    Inventors: Nicole BUSCHMANN, Robin Alec FAIRHURST, Pascal FURET, Bo HAN, Thomas KNÖPFEL, Catherine LEBLANC, Lv LIAO, Robert MAH, Franck MALLET, Julie MARTZ, Can WANG, Jing XIONG, Xianglin ZHAO
  • Bacterial iodoperoxidases from , methods of preparation and uses thereof
    Patent number: 9353354
    Abstract: The present invention concerns iodoperoxidases from Zobellia galactanivorans, isolated nucleic acids encoding same, as well as methods for preparing these enzymes. Moreover, the invention is also directed to the use of such iodoperoxidases in a wide range of industrial, pharmaceutical, medical, cosmetics, and ecological applications, as well as in the food industry.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: May 31, 2016
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Catherine Leblanc, Ludovic Delage, Gurvan Michel, Etienne Rebuffet, Mirjam Czjzek, Philippe Potin
  • Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
    Publication number: 20160102092
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: December 17, 2015
    Publication date: April 14, 2016
    Applicant: Novartis AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Thomas Knöpfel, Catherine Leblanc, Lv Liao, Robert Mah, Pierre Nimsgern, Sebastien Ripoche, Jing Xiong, Bo Han, Can Wang, Xianglin Zhao
  • Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
    Patent number: 9266883
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: February 23, 2016
    Assignee: Novartis AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Thomas Knöpfel, Catherine Leblanc, Lv Liao, Robert Mah, Pierre Nimsgern, Sebastien Ripoche, Jing Xiong, Bo Han, Can Wang, Xianglin Zhao
  • IP Receptor Agonist Heterocyclic Compounds
    Publication number: 20150376183
    Abstract: The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed.
    Type: Application
    Filed: February 11, 2014
    Publication date: December 31, 2015
    Applicant: Novartis AG
    Inventors: Rebecca BUTLER, Catherine LEBLANC, Stephen Carl MICKEOWN, Steven John CHARLTON
  • Salts of 7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid as IP receptor agonists
    Patent number: 9174985
    Abstract: The invention relates to salts of (7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid which are useful for treating diseases affected by the activation of the IP receptor, pharmaceutical compositions that contain the salts and processes for preparing the salts are also described.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: November 3, 2015
    Assignee: Novartis AG
    Inventors: Catherine Leblanc, Stephen Carl McKeown, Anett Perlberg, Nicola Tufilli
  • Pyrrolopyridine derivatives and their use as CRTH2 antagonists
    Patent number: 9169251
    Abstract: There are provided according to the invention compounds of formula (I) in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: October 27, 2015
    Assignee: Novartis AG
    Inventors: Kamlesh Jagdis Bala, Catherine Leblanc, David Andrew Sandham, Katharine Louise Turner, Simon James Watson, Lyndon Nigel Brown, Brian Cox
  • Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
    Patent number: 9132127
    Abstract: The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. Examples of compounds of the invention include the compounds according to Formula Ia, or a pharmaceutically acceptable salt thereof, and the compounds of the examples.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: September 15, 2015
    Assignee: Novartis AG
    Inventors: Steven John Charlton, Catherine LeBlanc, Stephen Carl McKeown
  • Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
    Patent number: 9115129
    Abstract: The present invention provides substituted pyrido[2,3-b]pyrazines which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such substituted pyride[2,3-b]pyrazines are also encompassed.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: August 25, 2015
    Assignee: Novartis AG
    Inventors: Steven John Charlton, Catherine Leblanc, Stephen Carl McKeown
  • Imidazo-pyridine derivatives as activin-like receptor kinase (ALK4 or ALK5) inhibitors
    Patent number: 9079897
    Abstract: Compounds of formula (I): in free or salt or solvate form, where X, R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: July 14, 2015
    Assignee: NOVARTIS AG
    Inventors: Catherine Leblanc, Cathy Ritchie, Duncan Shaw, Nikolaus Johannes Stiefl
  • Substituted pyrrolo[2,3-B]pyrazines for the treatment of disorders and diseases
    Patent number: 9073932
    Abstract: The present invention provides compounds of formula (Ia) and (Ib) which activate the IP receptor, processes for preparing them, pharmaceutical compositions comprising said compounds and uses thereof. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: July 7, 2015
    Assignee: Novartis AG
    Inventors: Claire Adcock, Catherine Leblanc
  • Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
    Publication number: 20150119385
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: October 24, 2014
    Publication date: April 30, 2015
    Applicant: Novartis AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Thomas Knöpfel, Catherine Leblanc, Lv Liao, Robert Mah, Pierre Nimsgern, Sebastien Ripoche, Jing Xiong, Bo Han, Can Wang, Xianglin Zhao
  • SUBSTITUTED PYRROLO[2,3-B]PYRAZINE COMPOUNDS AND THEIR USE
    Publication number: 20150094312
    Abstract: The present invention provides compounds of formula (Ia) and (Ib) which activate the IP receptor, processes for preparing them, pharmaceutical compositions comprising said compounds and uses thereof. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients.
    Type: Application
    Filed: December 10, 2014
    Publication date: April 2, 2015
    Inventors: Claire Adcock, Catherine Leblanc
  • Substituted pyrrolo[2,3-B]pyrazine compounds and their use
    Patent number: 8937069
    Abstract: The present invention provides compounds of formula (Ia) and (Ib) which activate the IP receptor, processes for preparing them, pharmaceutical compositions comprising said compounds and uses thereof. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: January 20, 2015
    Assignee: Novartis AG
    Inventors: Claire Adcock, Catherine Leblanc
  • Salts of an IP Receptor Agonist
    Publication number: 20150011555
    Abstract: The invention relates to salts of (7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid which are useful for treating diseases affected by the activation of the IP receptor, pharmaceutical compositions that contain the salts and processes for preparing the salts are also described.
    Type: Application
    Filed: January 11, 2013
    Publication date: January 8, 2015
    Applicant: NOVARTIS AG
    Inventors: Catherine Leblanc, Stephen Carl McKeown, Anett Perlberg, Nicola Tufilli
  • IP receptor agonist heterocyclic compounds
    Publication number: 20150005311
    Abstract: The present invention provides heterocyclic derivatives which activate the IP receptor, processes for preparing them, pharmaceutical compositions comprising said derivatives and uses thereof. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients.
    Type: Application
    Filed: January 11, 2013
    Publication date: January 1, 2015
    Applicant: NOVARTIS AG
    Inventors: Steven Carl Chatlton, Catherine Leblanc, Stephen Carl Mckeown
  • IP receptor agonist heterocyclic compounds
    Publication number: 20140378463
    Abstract: The present invention provides heterocyclic derivatives which activate the IP receptor, processes for preparing them, pharmaceutical compositions comprising said derivatives and uses thereof. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients.
    Type: Application
    Filed: January 11, 2013
    Publication date: December 25, 2014
    Applicant: NOVARTIS AG
    Inventor: Catherine Leblanc
  • IP receptor agonist heterocyclic compounds
    Publication number: 20140357642
    Abstract: The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed.
    Type: Application
    Filed: January 11, 2013
    Publication date: December 4, 2014
    Applicant: NOVARTIS AG
    Inventors: Steven Carl Chatlton, Catherine Leblanc, Stephen Carl McKeown
  • IP receptor agonist heterocyclic compounds
    Publication number: 20140357641
    Abstract: The present invention provides heterocyclic derivatives which activate the IP receptor, processes for preparing them, pharmaceutical compositions comprising said derivatives and uses thereof. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients.
    Type: Application
    Filed: January 11, 2013
    Publication date: December 4, 2014
    Applicant: NOVARTIS AG
    Inventors: Gurdip Bhalay, Steven Carl Chatlton, Mark Patrick Healy, Catherine Leblanc, Stephen Carl McKeown
  • PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS
    Publication number: 20140309254
    Abstract: There are provided according to the invention compounds of formula (I) in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.
    Type: Application
    Filed: June 26, 2014
    Publication date: October 16, 2014
    Inventors: Kamlesh Jagdis Bala, Catherine Leblanc, David Andrew Sandham, Katharine Louise Turner, Simon James Watson, Lyndon Nigel Brown, Brian Cox